The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Overcoming off-target toxicities associated with CAR-Ts in AML
Alex Bataller, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the challenge of using CAR T-cells in acute myeloid leukemia (AML) due to shared targets on both AML cells and healthy cells. He suggests that the next steps involve modifying CAR constructs or hematopoietic progenitors to avoid off-target toxicities. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
